Compare Amazon.com Inc (AMZN) vs Novartis AG (NVS) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Amazon.com Inc vs Novartis AG — how do they compare? Amazon.com Inc trades at $244.84 (market cap $2.64T), while Novartis AG trades at $153 (market cap $293.03B). The key difference: Amazon.com Inc is far larger — about 9× Novartis AG's market cap, and Novartis AG pays a 3.08% dividend while Amazon.com Inc pays none. Which is the better fit depends on your goals.
| AMZN | NVS | |
|---|---|---|
Market Cap | $2.64T | $293.03B |
Volume | 3,931,282 | — |
Sector | Consumer Cyclical | Health |
52-Week High | $274.95 | $168.62 |
52-Week Low | $198.79 | $113.50 |
Enterprise Value | $2.71T | $333.05B |
Dividend Yield | — | 3.08% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Amazon (AMZN) trades at $245.34, down 0.69% over the past day, with a bullish technical outlook supported by moving averages and strong support at $241. The company reported robust fundamentals with 2025 revenue of $716.92B and net income of $77.67B, reflecting a 10.83% margin. Recent Q1 2026 earnings beat expectations with EPS of $2.78 vs. $1.63 expected. Operating cash flow reached $139.51B in 2025, though heavy investing outflows continue for growth initiatives.
Outlook remains positive with 88.3% analyst buy ratings and a $320.75 consensus price target, implying significant upside. Key risks include intense competition in retail and cloud, high valuation multiples, and macroeconomic sensitivity. Growth drivers include AWS expansion and AI investments, but execution on capex and margin sustainability are critical for continued shareholder value.
Novartis (NVS) trades at $154.05, down 0.37% with a bullish technical signal supported by moving averages. The company demonstrates strong profitability with 75.38% gross margins and 35.21% ROE, though recent Q1 2026 earnings missed expectations. Recent developments include the $1.5B Myricx Bio acquisition expanding oncology capabilities and positive clinical trial results for neuromuscular and skin disorder treatments.
Investment outlook remains favorable with analyst consensus leaning hold (68%) amid solid fundamentals. Key opportunities include pipeline expansion through acquisitions, while risks involve execution of recent deals and competitive pressures in pharmaceuticals. The stock presents a balanced profile for long-term investors seeking healthcare exposure.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Amazon.com Inc
Amazon.com, Inc. is an online retailer that offers a wide range of products. The Company products include books, music, computers, electronics and numerous other products. Amazon offers personalized shopping services, Web-based credit card payment, and direct shipping to customers. Amazon also operates a cloud platform offering services globally.
Read more on AMZN →About Novartis AG
Novartis develops and manufactures healthcare products through two segments: Innovative Medicines and Sandoz. It generates the vast majority of its revenue from Innovative Medicines segment consisting global business franchises in oncology, ophthalmology, neuroscience, immunology, respiratory, cardio-metabolic, and established medicines. The company sells its products globally, with the United States representing close to one third of total revenue.
Read more on NVS →
